A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

• Published in: Clinical pharmacology and therapeutics Vol. 79; no. 1; p. 103
• Main Authors: Sim, Sarah C, Risinger, Carl, Dahl, Marja-Liisa, Aklillu, Eleni, Christensen, Magnus, Bertilsson, Leif, Ingelman-Sundberg, Magnus
• Format: Journal Article
• Language: English
• Published: United States 01.01.2006
• Subjects: Animals; Anticonvulsants - pharmacokinetics; Antidepressive Agents - pharmacokinetics; Antidepressive Agents - therapeutic use; Aryl Hydrocarbon Hydroxylases - genetics; China - epidemiology; Cytochrome P-450 CYP2C19; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors - pharmacokinetics; Enzyme Inhibitors - therapeutic use; Ethiopia - epidemiology; Gene Frequency; Genes, Reporter - genetics; Genetic Variation; Genotype; Humans; Male; Mephenytoin - pharmacokinetics; Mice; Mixed Function Oxygenases - genetics; Mutation; Omeprazole - pharmacokinetics; Omeprazole - therapeutic use; Phenotype; Plasmids - genetics; Proton Pump Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sweden - epidemiology; Transfection
• ISSN: 0009-9236
• DOI: 10.1016/j.clpt.2005.10.002

Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP) 2C19 enzyme. A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any genetic background. The 5...